UNSPSC 51401802: Clotiazepam

This classification denotes a sedative and hypnotic with the molecular formula C16H15ClN2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZCN055599V, chemically known as 5-(o-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-2h-thieno(2,3-e)-1,4-diazepin-2-one but generally known as clotiazepam, which bears US NIH Compound Identifier 2811. European Medicines Agency schedules Clotiazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06773MIG.

UNSPSC 51401802 Clotiazepam is a Commodity code nominally designating a benzodiazepine pharmaceutical product; however, recent state and local procurement activity under this code does not center on clotiazepam itself but instead spans broader pharmaceutical and medical-supply procurement including naloxone, generic multi-source pharmaceuticals, over-the-counter products, and drug deactivation systems. State and local issuers—including county health departments, state health and human services agencies, and multistate cooperative purchasing alliances—are using the code to solicit manufacturers and distributors of pharmaceutical products, medical devices, and related goods that support community health initiatives, substance-abuse response programs, and pharmacy benefit management. The actual buying encompasses procurement of finished pharmaceutical units for direct delivery to community health facilities, establishment of manufacturer contracts for distribution through authorized wholesalers, and procurement of ancillary medical equipment such as safe drug deactivation systems.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023; the contract includes a two-year initial term with one-year renewal option and potential FEMA funding with associated federal compliance requirements. The Texas Health and Human Services Commission released RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed through three authorized wholesalers, with a response deadline of March 26, 2026, contract effectiveness July 1, 2026, and weighted evaluation favoring price competitiveness at 75 percent. The mismatch between the code name and actual recent procurement activity suggests misclassification in the source data rather than genuine clotiazepam-specific demand at state and local level.